Remove Cell Based Assays Remove Pharmacokinetics Remove Research
article thumbnail

Accelerating Drug Discovery Through Repurposing

DrugBank

The journey from bench to bedside often spans over a decade, consuming billions of dollars in research and development (R&D) expenditure, with a significant probability of failure at each phase. For example, researchers utilized gene expression data to determine the anti-ulcer drug cimetidine as a possible treatment for colorectal cancer.

article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog: Drug Discovery

The definition goes on to list potential options for such tests: cell-based assays, organ chips and microphysiological systems, computer modeling, other nonhuman or human biology-based test methods such as bioprinting, as well as animal tests. FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ChEMBL 34 is out!

The ChEMBL-og

A company research code, or Clinical Trial intervention name, is assigned if no standardised name is available. For virtual parent compounds, progress has been made towards assigning a distinct pref_name (typically based on the FDA GSRS preferred name) that differs from the child compound name. University of Dundee: T.

article thumbnail

Inside The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials–Sophisticated Bioanalytical Approaches to Support Complex Modalities

Alta Sciences

Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic , and safety data in clinical trials. WHAT IS THE ALTASCIENTIST?